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ARTICLE OPEN
Point of care microspirometry to facilitate the COPD
diagnostic process in primary care: a clustered randomised trial
Tjard R. Schermer1, Maria Vatsolaki1,2, Robbert Behr3, Joke Grootens1, Riet Cretier1, Reinier Akkermans1, Joke Denis4, Patrick Poels5 and
Lisette van den Bemt 1
We studied if pre-bronchodilator FEV1/FEV6 determinations with microspirometers by GPs improve the diagnostic process for COPD
in a 6–8 month clustered randomised controlled trial in Dutch general practices (http://www.trialregister.nl: NTR4041). GPs allocated
to microspirometry (MI) used COPD-6® microspirometers in patients ≥50 years old with a smoking history and respiratory
complaints that could indicate undiagnosed COPD and ask to refer patients for full spirometry if MI was positive (FEV1/FEV6 <0.73).
Introduction of the COPD-6® was postponed in the usual care (UC) group. GPs of both study arms were asked to list all patients that
fulﬁlled study criteria and at the end of the study we screened the electronic medical record system for number of patients that
fulﬁlled study criteria and visited their GP within the study period. Main end point was a documented diagnostic conclusion of
COPD within 3 months after the patient’s visit. We used multilevel logistic regression with correction for relevant covariates. Next,
we described the process of care. 21 practices (88 GPs) participated and 416 possible undiagnosed COPD patient visited these
practices in the study period. 78 (of 192 visiting) subjects were listed by MI GPs and diagnostic conclusions were documented in
77%, compared to 61 listed (of 224 visiting) subjects and 44% with documented diagnostic conclusions by UC GPs (Odds Ratio: OR:
4.3, 95%CI: 1.6–11.5). Microspirometry improved the diagnostic process for possible underlying COPD in patients who consulted
their GP with respiratory symptoms, but the majority of possible undiagnosed COPD patients remained unrecognised by GPs.
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INTRODUCTION
Point of care (POC) tests are innovative diagnostic tests that are
carried out on site during a patient visit, with very rapid test
results.1 POC tests could optimise health care by enhancing
diagnostic procedures, improving medical decisions on the one
hand, and increase efﬁciency of care by reducing unnecessary
referrals and more advanced diagnostic testing on the other hand.
One diagnostic routine in primary care that could beneﬁt from a
valid POC test is the detection of chronic obstructive pulmonary
disease (COPD).
The hallmark of COPD is a chronic airﬂow obstruction that is
objectiﬁed by a post-bronchodilator (BD) spirometry test.2
Diagnostic spirometry requires time (usually between 30–45min)
and standardised procedures that cannot be integrated in a
regular patient visit to the general practitioners’ (GP) ofﬁce.3,4 GPs
consider the lack of objective information during consultation an
important barrier in the diagnostic process for COPD.5 For
instance, it remains difﬁcult to differentiate between a common
respiratory infection and COPD in a patient who consults with
respiratory symptoms. This is an important reason why COPD is
widely underdiagnosed in primary care, with estimates that vary
between 45 and 85% among subjects at risk.6,7
Forced expiratory volume in 6 s (FEV6) is the volume of air that is
exhaled in the ﬁrst 6 s under forced conditions, and can serve as a
surrogate for forced vital capacity (FVC).8 In the past few years,
small and inexpensive handheld devices that measure forced
expiratory volume in 1 s (FEV1)/ FEV6 ratio (microspirometers) have
become available. In a previous study, we found that the negative
predictive value of a pre-bronchodilator FEV1/FEV6 <0.73 as
measured with a microspirometer to rule out airway obstruction
is high in a primary care population at risk of COPD (i.e., 96.3%).9
Other studies found comparable results.10–12 Thus, microspirom-
eters could help GPs to substantiate airway obstruction more
easily and immediately during a regular consultation of an ‘at-risk’
subject. When indicated, the subject can be scheduled for further
diagnostic spirometry testing after that. This could facilitate the
pathway to an earlier diagnosis of COPD, and at the same time
lead to more efﬁcient use of full diagnostic spirometry testing.
Studies that focussed on screening (i.e., case ﬁnding) for COPD
found microspirometry to be a valid method and signiﬁcantly
better than using screening questionnaires.10,13–15 But what if
microspirometry is used in routine general practice settings as a
POC test for COPD? This could potentially reduce underdiagnosis
of COPD while avoiding the need for screening initiatives to
identify missed COPD cases in primary care populations.
We aimed to study the effect of the introduction of
microspirometers in real-life general practice care as a POC test
for COPD. We hypothesised that the use of microspirometry would
result in a higher proportion of recorded diagnostic conclusions
for patients at risk for COPD who visit their GP with respiratory
symptoms, compared to usual care conditions.
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RESULTS
This study was carried out in 21 general practices comprising 88
GPs (10 MI practices, Fig. 1). None of the practices dropped out. 14
practices (5 MI) agreed to extent the study period with another
two months because of limited numbers of subjects on their
summary lists after the initial 6-month period. All but one GP in
the MI group passed the exam at the end of the e-learning. The
total number of subjects at risk for COPD who visited the practices
during follow-up was 416 (192 subjects in MI). There were no
subjects who choose to opt-out. Among the subjects who
attended the GP ofﬁce and fulﬁlled the study criteria, there were
more females than males (Table 1). On the basis of the lists
generated from the practices’ medical record systems, the number
of eligible subjects that visited the practices within the study
period varied between 3 and 43 per practice.
More subjects who had visited the practice during the study
period and fulﬁlled the study criteria In the MI group were listed
on the practices’ summary lists compared to UC (41 vs. 27%).
Figure 2 shows the diagnostic process of subjects that were put on
the summary lists in the IM and UC groups in more detail. 57% of
the executed diagnostic spirometry tests of subjects with a pre-BD
FEV1/FEV6 <0.73 showed airﬂow obstruction (i.e., post-BD FEV1/
FVC < 0.7). Seven subjects were referred for spirometry despite a
negative microspirometry test. Only one of these tests showed
airﬂow obstruction. In UC group practices, 29% of diagnostic
spirometry tests in subjects on the summary lists were positive. In
the appendix (Fig. 1) the diagnostic process of the unlisted
patients are visualised.
A diagnostic conclusion was more likely to be drawn within
3 months in the IM group (n= 60, 77%) for subjects recorded on
practices’ summary lists compared to UC group (n= 27, 44%; OR:
4.3, 95%CI: 1.6–11.5). Moreover, 3 patients were diagnosed with
asthma in the IM group compared to none in the UC group. No
differences between the IM and UC groups were found for
subjects that were not listed on the summary lists by the GPs (IM
n= 34, 30%, UC n= 65, 49%; OR: 0.7, 95%CI: 0.3–1.5).
DISCUSSION
This study, to our knowledge, is the ﬁrst to look at the impact of
introducing microspirometers on the diagnostic process in
subjects at risk of COPD in a routine general practice care setting.
In subjects who were identiﬁed as being at risk for COPD by their
GP, the diagnostic process was completed and reported more
often when the GP had a microspirometer available. Moreover, the
use of diagnostic spirometry appeared to be more efﬁcient in the
microspirometry group (i.e., more tests were positive), although
the number of subjects for this analysis was small and the
difference was not statistically signiﬁcant. However, no further
investigation was initiated in both study groups in the majority of
subjects at risk for COPD, despite the fact that they consulted their
GP with respiratory symptoms and ﬁt the risk proﬁle for COPD.
The GPs who received the microspirometer seemed to be more
aware of COPD compared to GPs that were allocated to usual care,
as can be deduced from the higher proportion of eligible subjects
that were placed on the summary lists (41 vs. 27%). Moreover, the
diagnostic conclusion was more often registered for those who
were put on the summary list in the MI group. This observation
suggests that POC microspirometry could reduce COPD under-
diagnosis in primary care.
Another way to reduce underdiagnosis of COPD is case ﬁnding
using a screening questionnaire, as has been applied in a recent
Follow-up
Enrolment Practices invited (n = 117) 
♦   Declined to participate or no response (n = 94) 
♦   Declined participation before randomization (n = 2) 
Practices randomized (n = 21) 
Allocation
Allocated to usual care (UC) 
(n = 11, 52 GPs) 
♦ Received allocated intervention (n = 11) 
Allocated to microspirometry intervention (MI) 
(n = 10 practices, 36 GPs) 
♦ Received allocated intervention (n = 10) 
Eligible subjects (at risk for COPD) that visited 
practice (n = 224)
Eligible subjects (at risk for COPD) that visited 
practice (n = 192) 
Not put on summary 
list (n = 163) 
Put on summary 
list (n = 61) 
Not put on summary 
list (n = 114)
Put on summary 
list (n = 78)
*  diagnostic conclusion recorded in the patient record within 3 months after initial GP consultation for respiratory symptoms 
Analysis 
Confirmed COPD in 
record* (n = 40)
Confirmed COPD 
in record* (n = 27) 
Confirmed COPD in 
record* (n = 30)
Confirmed COPD 
in record* (n = 60)
Fig. 1 Flow Diagram
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Dutch study in general practices.16,17 Of the 3715 questionnaires
that were sent out in this opportunistic primary care case ﬁnding
strategy, only 48 new COPD cases were found. One of the reasons
for this low yield is that only 14% of subjects that ﬁlled out the
questionnaire were at risk for COPD and could be referred for
diagnostic spirometry, while in our study 55% of the micro-
spirometry tests resulted in a referral. Moreover, the attendance
rate for diagnostic spirometry testing is higher in our study (86 vs.
54%). A possible explanation for the lower rate of no-show is that
the outcome of a microspirometry test is more tangible for
patients than a score on a questionnaire. Some studies have
compared the results of case ﬁnding with a questionnaire and
microspirometry head-to-head and conclude that the speciﬁcity is
much higher for microspirometry and the sensitivity slightly lower
or comparable.15,18 Moreover, a recent publication showed that
the added value of a screening questionnaire next to micro-
spirometry is low.14
Strengths and limitations of our study
We executed a real-life study and analysed the results from a real-
life perspective. For example, all spirometry results in the
microspirometry group were analysed, including those that were
requested by the GP after a negative microspirometry test (i.e.,
FEV1/FEV6 ≥ 0.73). In daily primary care, GPs can also decide to
order a diagnostic spirometry test despite a negative result.
Another strength is that, we were the ﬁrst to include a control
group to enable comparison with usual care. Moreover, we
veriﬁed the documented number of diagnostic conclusions in the
subjects’ medical records. This outcome was considered clinically
relevant as treatment is guided by conﬁrmed or refuted COPD
diagnoses and only documented conclusions are likely to change
disease management in individual cases.
A limitation of the study is that GPs may have had good reasons
not to put particular subjects on their summary list, reasons that
were not recorded in the subjects’ medical records (e.g., terminal
ill spouse). The location of the practices (which varied greatly
between the two groups) may have inﬂuenced ﬁndings. Because
good access to diagnostic spirometry facilities are available, we do
not feel that this has inﬂuenced our results. Next, in our study, ‘at
risk’ subjects should have smoked at least for three months.
Cumulative cigarette smoke exposure is a better indicator, but
more difﬁcult to determine. Because of the pragmatic nature of
the trial, we decided to ask for months of smoking. Another
limitation is that we initially planned to use another deﬁnition for
‘diagnostic procedure completed’ in our study protocol. We
planned to compare the proportion of patients that had either a
conﬁrmed or refuted presence of airﬂow obstruction. However,
only during the data analysis we realised that a negative
microspirometry result should also be considered as a refuted
airﬂow obstruction and that because of this, the outcome and
intervention were ‘entwined’. The result of the analysis on the
original deﬁnition of a completed diagnostic procedure is
provided in the appendix and shows similar results as the slightly
modiﬁed outcome that is presented in this paper.
Implications and recommendations
This study has shown that POC microspirometry is a feasible
strategy in routine care that can be implemented without
substantial additional time investment or costs in general
practices that already have good access to diagnostic spirometry.
As microspirometers have originally been developed for single-
patient use, it is important to use the more expensive one-way
valve mouthpieces in order to prevent cross-infections. Previous
studies used another type of microspirometers (like PiKo-6®, nSpire
Health, Inc) with similar results in test quality, and therefore, it
seems that other devices than the COPD-6® can be used for the
same purpose.10,18 However, little is known about the long-term
performance of these devices and the effect of day-to-day use in a
general practice. Unlike diagnostic spirometers, microspirometers
cannot be calibrated, so more information on the durability of the
devices is needed.
CONCLUSIONS
In conclusion, the introduction of POC microspirometry in general
practices resulted in more, and more efﬁcient diagnostic
spirometry testing in subjects at risk for COPD who consulted
their GP with respiratory symptoms. Although microspirometry
improved the diagnostic process, the majority of possible
undiagnosed COPD patients remained unrecognised by the GPs
who were involved in the study.
METHODS
Study design
We performed a cluster-randomised trial to evaluate the added value of
FEV1/FEV6 measurement using a microspirometer in the diagnostic work-
up of subjects at risk for COPD who consult their GP with respiratory
complaints. Clusters were general practices in the city of Nijmegen and
surroundings, the Netherlands. Subject inclusion started in the ﬁrst
practice in January 2013 and ﬁnished in the last practice in December
2014. The study was exempted from ethics review by the medical ethics
review board of the Radboud University Medical Center (2012/483). GPs
asked permission of subjects to record information for scientiﬁc purposes.
Study brochures were available in all practices and no identiﬁable
information of patients was collected. The study was conducted according
to the principles of the Declaration of Helsinki (Fortaleza, Brazil, October
Table 1. Practice and subject characteristics
MI group UC Group
General practice level n= 10
practices
n= 11
practices
Total n of GPs 36 52
GPs per practice, n (%)
≤3 GPs 5 (50) 3 (27)
4–5 GPs 4 (40) 4 (36)
≥6 GPs 1 (10) 4 (36)
Practice population sizea, mean (SD) 5450 (3017) 6389 (3111)
Diagnosed COPD patients per practice,
mean (SD)
101 (54) 111b (63)
Location of practice, n (%)
Urban 3 (30) 9 (82)
Suburban 4 (40) 0 (0)
Rural 3 (30) 2 (18)
Subjects >50 years old, % (SD) 35 (8.1) 29 (7.1)
Subject level n=
192 subjects
n=
224 subjects
Males, n (%) 76 (40) 99 (45)
Agec, mean (SD) 64.0 (8.3) 62.7 (7.7)
Smoking habitd, n (%)
Current 71 (37) 86 (38)
Former 105 (55) 113 (51)
Unknown 16 (8) 25 (11)
SD standard deviation
aNumber of registered subjects in the practice
bMissing information of 1 usual care practice
cAge missing for 3 subjects of the usual care group
dSubjects with unclear, but existing smoking history were included in the
former smokers group
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2013) and Personal Data Protection Act. The study was registered in the
Dutch Trial Register (at http://www.trialregister.nl: registration number
NTR4041).
Recruitment of practices and inclusion of study subjects
We invited general practices through primary care cooperatives and an
academic general practice network. GPs received an incentive of 250 euro
for their participation. Practices could not participate when they had
screened their practice population for undiagnosed COPD in the last 5
years and/or were living in a housing development area, where
predominantly younger individuals live.
Study participants were subjects who attended a GP in one of the
participating practices with respiratory complaints during the study period.
The following inclusion criteria applied: 50 years or older; (ex-)smoker with
a smoking history of at least 3 months; visited the GP with at least one of
the following complaints: dyspnoea, cough, mucus hypersecretion, and/or
wheezing; no previous diagnosis of asthma and/or COPD; no diagnostic
spirometry test in the past 5 years according to the medical record.
Subjects for microspirometry were not preselected with a questionnaire, as
ﬁlling out a questionnaire by the patient, calculating a score from the
questionnaire items and performing microspirometry during a routine GP
consultation is not feasible.
Group allocation and blinding
Practices were allocated to one of the two study arms by means of a
minimisation procedure using MINIM software.19 Practices were equally
distributed for number of registered patients aged 50+ years in the
general practice above versus equal to or below the Dutch norm. One of
the authors (LB) generated the random allocation sequence, and assigned
practices to study arms. The allocation sequence was kept at Radboud
University Medical Center. Due to the type of intervention the participating
GPs could not be blinded for the allocation of their practice. The study’s
statistician (RA) was unaware of group allocation during analyses, and the
interpretation of results took place before group allocation was revealed.
Microspirometry intervention and usual care group
GPs in practices allocated to the microspirometry intervention (MI) group
followed a 90-min e-learning educational module and instructions on how
to use the microspirometry device [COPD-6®, Model No 4000, Vitalograph
Ltd, Ennis, Ireland] before the start of the study period in their practice.20 A
total of 3 forced blows into the microspirometer until the stop signal of the
device sounded after 6 s were recommended. The microspirometer does
not provide any graphical tracings. However, the device does give the
operator some feedback about the quality of the forced expiratory
manoeuvres during testing. If an exclamation mark appears on the display,
this means that the last blow was not a good quality blow and the subject
should blow again. GPs were instructed to refer subjects with FEV1/FEV6 <
0.73 for further diagnostic spirometry testing. MI group GPs were
instructed to list all eligible subjects during the study period on a
summary list and to use the microspirometer in these subjects when they
felt this was indicated and possible timewise.
GPs in the usual care (UC) group did not have access to the e-learning
and microspirometers, and were instructed to provide ‘care as usual’ in
terms of referring eligible subjects for further diagnostic spirometry testing
when they felt this to be indicated. Like in the IM group, UC group GPs
were instructed to record subjects who fulﬁlled the eligibility criteria on the
summary list.
The planned duration of the study period per practice was 6 months.
However, the number of subjects on the summary lists of some practices
was smaller than anticipated, and therefore, we asked these practices to
extent the study period with another 2 months.
Diagnostic spirometric tests
Diagnostic spirometry testing took place in the general practices. Quality of
test evaluation and result selection had to be in line with recommenda-
tions by international spirometry guidelines.21 Pre- and post bronchodi-
lator (BD) spirometric measurements were performed, the latter 15 min
after administration of four doses of 100mcg aerosolized salbutamol by a
Volumatic® spacer. Predicted values for FEV1 and FVC were calculated
based on the Global Lung function Initiative reference equations.22
Microspirometry group
(n = 78) 
Microspirometry test:
pre-BD FEV1/FEV6 < 0.73
(n = 42, 55% of successful tests)
Microspirometry test:
pre-BD FEV1/FEV6 ≥ 0.73
(n = 34, 45% of successful tests)
Microspirometry test failed/not
executed
(n = 2)
Referred for diagnostic
spirometry
(n = 49, 80%)
Diagnostic spirometry result
(n = 27, 55% of ordered test)
Post-BD FEV1/FVC < 0.7
(n = 11, 41% of spirometry
tests,18% of group)
Usual care group
(n = 61) 
Referred for diagnostic
spirometry
(n = 42, 100% of positive tests)
Referred for diagnostic
spirometry
(n = 7, 21% of negative tests)
Referred for diagnostic
spirometry
(n = 0)
Diagnostic spirometry result
(n = 36, 86% of ordered tests) 
Diagnostic spirometry result
(n = 7, 100% of ordered test)
Post-BD FEV1/FVC < 0.7
(n = 20, 1 missing, 57% of
spirometry tests)
Post-BD FEV1/FVC < 0.7
(n = 1, 14% of spirometry tests)
Post-BD FEV1/FVC < 0.7
(n = 21, 1 missing, 50% of spirometry tests, 27% of group)
COPD diagnosis in medical record
(n = 17, 22% of MI group)
COPD diagnosis in medical rec.
(n = 9, 15% of UC group)
Diagnostic conclusion within 3 month after initial consultation documented in patient record
(n = 60, 77% of MI group)
Diagnostic conclusions < 3mo in
patient record
(n = 27, 44% of UC group)
Fig. 2 Diagnostic process in subjects on the summary lists of practices in the microspirometry intervention group
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Data collection
After the study period, each practice printed a list from the electronic
medical record system of all subjects who had visited the practice during
the study period and fulﬁlled the following criteria: 50 years or older;
respiratory symptoms that could indicate COPD (dyspnoea (International
Classiﬁcation for Primary Care (ICPC) code R02), cough (R05), mucus (R25),
and/or wheezing (R03)); no diagnosis of asthma (R96) and/or COPD (R95)
on the visiting date; and no spirometry in the past 5 years. For all subjects
on the practice list, the following information was extracted manually from
their medical ﬁles: age; gender; smoking history; information on respiratory
diagnostic tests and test results; diagnostic conclusions (also when COPD
was ruled out and asthma); if applicable: time between the subject’s initial
consultation and the GP’s diagnostic conclusion; and whether or not the
subject had also been recorded on the summary list by their GP.
Outcomes
The primary outcome of the study was the proportion of subjects with a
recorded diagnostic conclusion that either conﬁrmed or refuted COPD as
evidenced by a lung function test result within 3 months after the initial GP
consultation. Apart from this outcome, the process from patient visit till a
diagnostic conclusion is described in detail for MI and UC group.
Sample size calculation
In 2014, the prevalence of COPD was 3.5% in general practices in the
Netherlands23, and estimates of COPD underdiagnosis in primary care
populations vary between 45–85%.6,7 A priori we assumed that (a) 30% of
subjects that visited their GP and were at risk of COPD would be tested in
the UC group and (b) that the use of microspirometry by GPs would
double this proportion to 60%. Moreover, we anticipated that at least 10
patients per practice would be listed on the summary list during the study
period. Accepting a power of 0.80, α of 0.05 and an intra-cluster correlation
of 0.10, and a drop-out of 6 practices, 22 practices had to be recruited.
Statistical methods
Unpaired t tests, Χ2 tests and Mann–Whitney U tests were applied to
compare practice, GP and subject characteristics between the IM and UC
groups, using IBM SPSS software (Chicago, IL, USA, version 22). Detailed
descriptive information on the diagnostic process is provided for both
study arms. Logistic regression modelling with correction for clustering on
practice level was used to evaluate the difference between MI and UC
groups for completed diagnostic process in 3 months after the initial GP
consultation (GLIMMIX procedure in SAS statistical software) (SAS Institute,
Cary, NC, USA). We tested the model for effect modiﬁcation and
confounding for the following variables: age, gender, smoking status,
respiratory symptoms, whether or not the subject had been put on the
summary list by the GP, and the follow-up time of the practice (6 vs.
8 months). Because being recorded on the summary list by the GP turned
out to be an effect modiﬁer in the analysis, odds ratios (ORs) are presented
separately for the comparison of patients on the summary list between IM
and UC groups, and for those who had not been put on the summary list
by their GPs. For all statistical tests, p < 0.05 was considered statistically
signiﬁcant and were tested two-sided.
Data availability
The data set generated and analysed during the study is currently not
publicly available as the Radboud University Medical Center is developing
a digital research environment where the data will be made available in
the near future (http://portal.umcn.nl/organisatie/im/Pages/
Datastewardship.aspx). Until then, the data can be made available by
the corresponding author on reasonable request.
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